SymBio Pharmaceuticals Limited

4582

TSE PrimePharmaceuticals

¥ -

You can review earnings summary, quarterly trends, full-year progress, and detailed income statement data.

descriptionIncome Statement (PL) Summary

Updated: 2026-08-10FY2026 Q2

Revenue

11.3100M JPY

YoY -37.7%

Operating Income

-36.4100M JPY

YoY -68.8%

Net Income

-60.3100M JPY

YoY -29.3%

EPS

-50.9JPY

YoY -3.1%

Performance Trend

Revenue, operating income and net income trend (last 5 periods)

RevenueOperatingNet Income

100.1億円

63.1億円

26.2億円

-10.8億円

-47.8億円

Rev: 82.6億円Op: 10.2億円NI: 20.3億円

Rev: 100.1億円Op: 19.6億円NI: 11.8億円

Rev: 55.9億円Op: -8.1億円NI: -19.6億円

Rev: 24.5億円Op: -38.8億円NI: -38.3億円

Rev: 13.1億円Op: -44.4億円NI: -47.8億円

2021/FY2022/FY2023/FY2024/FY2025/FY

Full-Year Progress

FY2026 Q2

Net Income83.6%

Revenue Progress4.700M

Revenue Forecast38.900M

Net Income Progress-36.200M

Net Income Forecast-43.300M

Income Statement Details

Unit: JPY

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan